ViewRay, Inc. announced that the German Research Foundation has purchased a MRIdian Linac for installation and patient treatments at the University Clinic Heidelberg as part of its initiative for MRI-based radiation therapy. The MRIdian Linac program will be headed by Medical Director and Professor Jürgen Debus, M.D., Ph.D., who also heads radiation oncology at the German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion Center (HIT) and the Marbug Heavy Ion Center (MIT). The University Clinic Heidelberg will be an important MRIdian research partner, helping to explore a wide array of topics including improved dose delivery through MRI-guidance and various clinical studies. The MRIdian Linac is the first, and currently the only, MRI-guided linear accelerator available for clinical use in Europe. DFG's purchase of the MRIdian Linac marks the first in Europe since ViewRay received its CE Mark approval in September. The MRIdian Linac is a next-generation linear accelerator-based MRI-guided radiation therapy system. Using the MRIdian Linac system, clinicians can see soft tissue, and visualize and adjust the dose in real-time.